No Data
No Data
Outperforming the Large Cap in the past 4 months! Hong Kong stocks for Innovative Drugs are gaining strength again, with Institutions expecting that the pharmaceutical main theme may run through the entire year.
① Hong Kong stocks of Innovative Drugs are strengthening again, which Bullish catalysts are Institutions focusing on? ② The Biomedical Index has outperformed the Large Cap for the past four months; how strong has its performance been this year?
From PD-1 to several leading ADCs, Lepu Biotech-B (02157) is facing a value re-evaluation.
The stock price has increased by nearly 78% this year, has Lepu Biopharma captured investors' hearts with its ADC drugs?
AI empowers the FDA! Drug approvals hit the 'fast-forward' button, and a large number of pharmaceutical companies may welcome a 'Gold' period.
The USA Food and Drug Administration (FDA) announced an accelerated plan on Thursday to fully implement AI applications across all subsidiary institutions by June 30, aiming to significantly expedite the approval process for new pharmaceuticals.
Hong Kong stocks are experiencing unusual movements | Lepu Biotech -B (02157) rose nearly 7% in the morning. CG Oncology announced the latest data on CG0070. The company holds rights in Greater China.
Lepu Biotech-B (02157) rose nearly 7% in the morning, and as of the time of writing, it has risen by 6.13%, priced at 4.5 Hong Kong dollars, with a transaction volume of 37.0727 million Hong Kong dollars.
LEPU BIO-B: 2024 Annual Report
Market Overview | All three major indices fell, with the Tech Index down nearly 1.5%; most Network Technology stocks retraced, with Meituan falling over 5%; Biomedical stocks performed remarkably, with Asymchem Laboratories rising over 11%.
Network Technology stocks fell across the board, with JD-SW down 6.19% and MEITUAN-W down 5.15%; Pharmaceutical stocks rallied, with Asymchem Laboratories up 11.50% and INNOVENT BIO up 6.80%; Apple Supplier stocks declined overall, with AAC TECH down 2.88% and FIH down 2.74%.